Nanobiotix Stock Rises 3.06% Midday Following Inclusion in Paris Indices

Significant Milestone with Index Inclusion

Nanobiotix's stock has increased by 3.06% at midday this Tuesday, December 23, priced at 20.20 euros compared to 19.60 euros at the previous day's close. This movement occurs in a context of moderate volumes with only 0.25% of the capital traded. Over the past week, the French biotech's stock has recorded a rise of 4.45%, confirming the bullish momentum that has been building for several weeks. The effective integration into the CAC Mid 60 and SBF 120 indices took place this Monday, marking a strategic milestone for the stock's valuation. Over three months, the increase reaches 81.33%, while on an annual scale, the stock has seen a spectacular surge of 530.9%, significantly outperforming the broader Paris market. This exceptional trajectory is explained by the continuous advancements in the company's clinical pipeline, notably in the development of its flagship candidate NBTXR3 in partnership with Johnson & Johnson.

Notable Shareholder Movements and Financial Strategy

In terms of shareholder activity, significant movements were observed in December. Goldman Sachs declared that it had exceeded the thresholds of 5% of the capital and voting rights on December 12, indirectly holding 7.43% of the capital, after dropping below 5% at the end of November. This upward repositioning by the American investment bank reflects sustained interest in the stock despite its strong appreciation since the beginning of the year. Financially, the French biotech benefits from a non-dilutive financing agreement with HealthCare Royalty that could reach up to 71 million dollars, extending its cash horizon until the beginning of 2028.

Technical Analysis and Future Outlook

From a technical standpoint, the RSI is positioned at 70, a level that precisely indicates the threshold of the overbought zone, suggesting a possible phase of consolidation in the short term following the recent progression. The stock price is above its 50-day moving average established at 18.52 euros, confirming the strength of the medium-term trend. The significant gap with the 200-day moving average, which stands at 9.19 euros, materializes the spectacular acceleration of the stock since the beginning of the year, with a differential of 119.8%. The MACD presents an encouraging configuration with a positive histogram at 0.04, the MACD line at 0.34 is above the signal line at 0.30, signaling potential for continuation of the bullish movement in the short term. The Bollinger Bands frame the price between 16.91 euros and 20.06 euros, with the stock trading close to the upper boundary, indicating sustained buying pressure. Volatility remains measured at 12.81% over a month, a relatively contained level for a biotechnological value in clinical development phase. The clinical catalysts expected in 2026 are major milestones that could significantly impact the stock's valuation in the coming months.